Connect with us

Health

Weight-loss experts predict 5 major treatment changes likely to emerge in 2026

Published

on

Weight-loss experts predict 5 major treatment changes likely to emerge in 2026

NEWYou can now listen to Fox News articles!

Big moves are continuing in the weight loss landscape in the new year following breakthrough research of GLP-1 medications and other methods.

Weight-loss experts spoke with Fox News Digital about their predictions for the most major changes to come in 2026.

No. 1: Shift to whole-body treatment 

Dr. Peter Balazs, a hormone and weight loss specialist in New York and New Jersey, shared that the most important shift is likely to label GLP-1 drugs as “multi-system metabolic modulators” rather than “simple weight loss drugs.”

MORE AMERICANS MAY BE CLASSIFIED AS OBESE UNDER NEW DEFINITION, STUDY SUGGESTS

Advertisement

“The treatment goal is no longer just BMI reduction, but total cardiometabolic risk mitigation, with effects now documented across the liver, heart, kidneys and vasculature,” he said.

“We are seeing a significant reduction in major adverse cardiovascular events … and progression of renal disease,” he went on.

The focus of GLP-1 drugs will widen beyond weight loss and diabetes, according to experts’ predictions. (iStock)

Philip Rabito, M.D., a specialist in endocrinology, weight loss and wellness in New York City, also shared that “exciting” advancements lie ahead for weight-loss drugs, including GLP-1s and GIPs.

OLDER AMERICANS ARE QUITTING GLP-1 WEIGHT-LOSS DRUGS FOR 4 KEY REASONS

Advertisement

“These next‑generation agents, along with novel combinations that include glucagon and amylin agonists, are demonstrating even more impressive weight‑loss outcomes than currently available therapies, with the potential for better tolerability and sustained results,” he told Fox News Digital.

“There is also tremendous optimism around new federal agreements with manufacturers that aim to make these medications more widely accessible and affordable for the broad population of patients who need them most.”

No. 2: More convenient dosing

The typical prescription for a GLP-1 medication is a weekly injection, but delivery and dosing may be changing to more convenient methods in 2026, according to Balazs.

OPRAH JOINS WAVE OF CELEBRITIES WHO REVEALED DRAMATIC WEIGHT LOSS IN 2025

A daily 25 mg pill version of Novo Nordisk’s Wegovy, a semaglutide designed to treat obesity, is now approved and available for chronic weight management, offering a non-injectable option for some patients.

Advertisement

A once-weekly oral GLP-1 is currently in phase 2 trials, as well as an implant that aims for three to six months of drug delivery, Balazs noted.

Incisionless weight-loss procedures will rise as a lower-risk option, according to experts. (iStock)

No. 3: Less invasive surgery

In addition to decreased risk during surgery for GLP-1 users, Balazs also predicted that metabolic surgery without incision will rise as a better option.

“Incisionless endoscopic procedures — like endoscopic sleeve gastroplasty (non-surgical weight-loss procedure that makes the stomach smaller from the inside) and duodenal mucosal resurfacing (non-surgical procedure that resets part of the small intestine to help the body better handle blood sugar) — [may become] more durable and widely available,” he said. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

“These offer significant metabolic benefits with shorter recovery and lower risk than traditional surgery.”

Rabito agreed that “rapid progress” in minimally invasive weight‑loss procedures is “opening powerful new options for patients who are hesitant to pursue traditional bariatric surgery.”

Bariatric surgery remains the most effective weight loss method, one specialist says. (iStock)

This avenue offers “meaningful and durable weight reduction with less risk, shorter recovery times and no external incisions,” the expert added.

Dr. Muhammad Ghanem, bariatric surgeon at the Orlando Health Weight Loss & Bariatric Surgery Institute, reiterated that surgery remains “the most successful modality for the treatment of obesity … with the highest weight loss and most durable outcomes as of yet.”

Advertisement

No. 4: Younger GLP-1 users

As Novo Nordisk’s Wegovy has been indicated for adolescents over 12 years old as an obesity treatment, Balazs commented that pediatric use of weight-loss drugs is “now a clinical reality.”

He predicted that other alternatives are likely to be approved in 2026 for younger users.

No. 5: High-tech, personalized access

Amid the growth of artificial intelligence, Balazs predicted an expansion in the clinical implementation of AI-driven weight-loss methods.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

This could include categorizing obesity into sub-types like “hungry brain,” “emotional hunger” and “slow burn” to personalize how therapy is prescribed while moving away from “trial and error,” he said.

Advertisement

Ghanem agreed that there will likely be a “big focus” on individualized testing for causes of obesity in 2026, as it’s a disease that can have “different causes in different people,” thus requiring different treatments.

AI and other digital opportunities will drive more access for weight-loss patients, experts say. (iStock)

The doctor anticipates that more patients will seek combinations of comprehensive treatments and programs.

“Patients are more aware that now we have a few weapons in our arsenal to combat obesity, and [they] are seeking a multidisciplinary and holistic approach,” Ghanem said.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

Treatment options will also turn digital with the rise of prescription digital therapeutics (PDTs) for weight loss, Balazs predicted.

“These are software applications delivering cognitive behavioral therapy, personalized nutrition and metabolic coaching through algorithms, often integrated with continuous glucose monitors, and reimbursed as medical treatments,” he said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Ghanem added that body composition analyzers, like DEXA scans, will likely be more widely used as awareness grows about the limitations of BMI and weight in assessing obesity.

Advertisement

Health

9 Ways To Reverse Stress-Related Weight Gain Fast—One Woman Shed 100 Lbs!

Published

on

9 Ways To Reverse Stress-Related Weight Gain Fast—One Woman Shed 100 Lbs!


Advertisement





Can Stress Cause Weight Gain? How to Lose Stress Weight Fast




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Weight-loss drugs may improve job prospects and dating odds for one group

Published

on

Weight-loss drugs may improve job prospects and dating odds for one group

NEWYou can now listen to Fox News articles!

A recent study suggests GLP-1-related weight loss may improve some women’s relationships and employment status.

Rebecca Diamond, professor of economics at Harvard University in Boston, independently published research that found an association between weight-loss medications and a change in women’s social and economic outcomes.

Diamond used the Understanding America Study, a panel survey from the University of Southern California, to compare women who started GLP-1s for weight loss to those who wanted to start but had not yet done so.

DR OZ LINKS OBESITY TO CHRONIC DISEASE SURGE, SAYS GLP-1S CAN ‘JUMPSTART’ BETTER HEALTH

Advertisement

The comparison considered body mass, health, income, employment, partnership status and well-being before treatment.

The study focused on women because they are more likely to use GLP-1s than men. It excluded people taking GLP-1 drugs for diabetes, as their use is driven by a medical condition rather than weight-loss demand.

Women who began GLP-1s for weight loss and were successful in losing weight experienced changes in relationship and employment status, according to the findings. (iStock)

Women who successfully lost weight with GLP-1 medications experienced changes across several life outcomes, including employment, marriage and cohabitation, according to the study.

Marriage and cohabitation rose 29% for single women after about 18 months.

Advertisement

DIVORCEES AND WIDOWS SHARE CONCERNING MENTAL HEALTH TRAIT, RESEARCHERS FIND

Among women who were not employed at the start of the study, job prospects increased by 27% after the same amount of time. Those who were already employed did not display any clear upward progress in their careers, however.

Diamond argues that these findings suggest part of the “female obesity penalty” comes from how people are judged when being matched up, either in a new relationship or a new job.

The findings say “more about societal bias than about the medication itself,” a doctor suggested. (iStock)

Dr. Peter Balazs, MD, a hormone and weight-loss specialist from New York and New Jersey, commented on these findings.

Advertisement

“The effects showed up during ‘new match’ situations, such as job interviews or dating, and not within existing jobs or relationships,” Balazs, who was not involved in the study, told Fox News Digital. “This says more about societal bias than it does about the medication itself.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Balazs said his patients often report feeling more confident and “visible” after weight loss, which could translate into better interview performance and networking.

CLICK HERE FOR MORE HEALTH STORIES

“Weight loss (commonly) improves confidence, which opens new business and relationship opportunities,” he went on. “Weight loss has hormonal impacts as well, so the normalization of hormones and the profound metabolic and psychological relief that comes with it can be a factor, too.”

Advertisement

“Weight loss (commonly) improves confidence, which opens new business and relationship opportunities,” an expert said. (iStock)

Dr. Krishna Vyas, a plastic surgeon at Blechman Plastic Surgery in New York, told Fox News Digital in a separate interview that many patients seek breast lifts or body contouring after significant GLP-1 weight loss, after which they find themselves “re-engaging with life.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“That confidence effect is real in the exam room,” said the surgeon, who also was not involved in the research. “This study, however, showed no clear improvement in depression, loneliness or life satisfaction, even as marriage and employment rates climbed dramatically.”

“The opportunities opened, yet the women didn’t report feeling better, which suggests it was largely the gatekeepers who changed, not the women.”

Advertisement

Potential limitations

Because this was an observational study rather than a randomized clinical trial, it could only show an association — not cause and effect. The findings are also considered preliminary because the paper has not yet been peer-reviewed, the author acknowledged.

“Additionally, since the study only looked at women, that introduces another layer of potential bias,” Balazs noted. “I’d be interested to see whether the findings would be the same if the study included men or compared them directly.”

“Weight loss has hormonal impacts as well, so the normalization of hormones and the profound metabolic and psychological relief that comes with it can be a factor, too,” an expert said. (iStock)

Another limitation is that the information from the individuals studied was self-reported, the expert noted. 

The researchers were also unable to determine whether people who found new jobs were earning more money.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“Additionally, even though GLP-1 users appeared to have better outcomes on paper, they did not report greater overall life satisfaction,” Balazs added. “That raises important questions about whether these external changes translate into meaningful improvements in well-being.”

Fox News Digital reached out to the study researcher and multiple human resources organizations requesting comment.

Continue Reading

Health

First death reported in Upper East Side Legionnaires’ disease outbreak as cases rise to 67

Published

on

First death reported in Upper East Side Legionnaires’ disease outbreak as cases rise to 67

NEWYou can now listen to Fox News articles!

New York City health officials announced Friday that the first person has died in connection with a growing Legionnaires’ disease outbreak on Manhattan’s Upper East Side as the number of confirmed infections continued to rise.

Advertisement

“I am saddened to report that one person has died in connection with the Legionnaires’ disease community cluster on the Upper East Side,” New York City Health Commissioner Dr. Alister F. Martin said in a statement.

“My deepest condolences are with their loved ones, and out of respect to their personal privacy, we will not be releasing any additional information on the individual.”

NYC HEALTH OFFICIALS WARN CENTRAL PARK VISITORS AFTER LEGIONNAIRES’ OUTBREAK GROWS ON UPPER EAST SIDE

A 3D illustration of Legionella pneumophila, the bacteria that causes Legionnaires’ disease, a severe form of pneumonia. (iStock)

The death comes as the outbreak has sickened 67 people as of Thursday night, up from 63 cases reported a day earlier. Twelve people remain hospitalized, according to city health officials.

Advertisement

Investigators are tracing the outbreak to Legionella pneumophila bacteria found in 76 cooling towers across the Upper East Side and one on the Upper West Side. Buildings that tested positive, including the Solomon R. Guggenheim Museum, have been ordered to clean and disinfect their cooling towers.

Legionnaires’ disease is a severe form of pneumonia caused by Legionella bacteria, which naturally occurs in water but can multiply in building water systems such as cooling towers. The illness can be treated with antibiotics if diagnosed early.

DEADLY LEGIONNAIRES’ DISEASE OUTBREAK SPARKS CONCERN IN MAJOR US CITY: KNOW THE SYMPTOMS

A blood sample tests positive for Legionella bacteria, which causes Legionnaires’ disease. (iStock)

Cooling towers, commonly found on rooftops, help regulate large building cooling systems and can release mist containing the bacteria. Health officials have emphasized that the outbreak is not linked to New York City’s drinking water or indoor air conditioning.

Advertisement

Health officials urged anyone who lives, works or has visited the affected area since late June and develops flu-like symptoms to contact a health care provider immediately.

Symptoms typically appear two to 14 days after exposure and include fever, cough, shortness of breath, muscle aches and headaches. The disease spreads through contaminated water droplets and is not spread from person to person.

New York City health officials are urging anyone who has visited Manhattan’s Upper East Side since late June to watch for symptoms of Legionnaires’ disease. (iStock)

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Older adults, smokers and people with chronic lung disease or weakened immune systems face the highest risk of severe illness. According to the Centers for Disease Control and Prevention, about 1 in 10 people diagnosed with Legionnaires’ disease die from complications.

Advertisement

City health officials said early diagnosis and prompt treatment with antibiotics can significantly improve outcomes for patients who become infected.

Continue Reading
Advertisement

Trending